ClinicalTrials.gg
Drug

Mesalamine clinical trials

Also written Mesalazine, Lialda and Asacol.

studies test it
94
open now
7
in phase 3
41
first study started
1999

How each study uses Mesalamine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Mesalamine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
24 Dec 1987 · ROWASA · NDA 019618 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Mesalamine
31
5-ASA
7
Mezavant
3
MMX mesalamine
2
SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine
2

Brand

Lialda
14
Asacol
11
Pentasa
9
Asacol 400 mg
2
Apriso ™
1

Development codes

SPD476
1
TP05
1
MAX-002
1

Other names

Mesalazine
27
Mesalazine 250Mg
1
Mesalazine 800 mg
1

Studies by the year they started

93 studies that test it; most in 2010 (11); 1 more planned to start later

Studies that test Mesalamine, by start year
YearStudies
19991
20001
20011
20021
20035
20042
20058
20064
20079
20087
20097
201011
20116
20125
20133
20143
20153
20162
20173
20192
20222
20232
20243
20251
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
17
Phase 2
17
Phase 3
41
Phase 4
18
No phase
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 57 · Other 37

Shire (13) · Dr. Falk Pharma GmbH (8) · Warner Chilcott (8) · Ferring Pharmaceuticals (7) · Tillotts Pharma AG (6) · SOFAR S.p.A. (4) · Bausch Health Americas, Inc. (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2)

Often tested with

Tested in the same studies.

Hydrocortisone (2) · Adrenal Cortex Hormones (2) · Budesonide (2) · Nitazoxanide (1) · Probiotic (1) · Lacticaseibacillus casei (1) · Tetomilast (1) · Tofacitinib (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test Mesalamine.

Studies

Open first, then newest update. How each study uses Mesalamine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 94

See all 94 studies that test Mesalamine →

Given beside what is tested · 21 — Mesalamine is usual care or a partner of the new treatment

Showing 20 of 21.

As the comparator · 19 — what is tested is compared with Mesalamine

Codes

What other systems call Mesalamine · ClinicalTrials.gg INT008722

  • MeSH (NLM) D019804MesalamineConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 4Q81I59GXCMESALAMINEConfirmed FDA, NLM
  • RxNorm 52582One source FDA
  • NCI Thesaurus C29249MesalamineOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.